左旋多巴毒性在帕金森病治疗中的临床相关性。

The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.

作者信息

Schapira Anthony H V

机构信息

University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, United Kingdom.

出版信息

Mov Disord. 2008;23 Suppl 3:S515-20. doi: 10.1002/mds.22146.

DOI:10.1002/mds.22146

PMID:18781678

Abstract

Levodopa is the 'gold standard' drug for the treatment of the motor symptoms of Parkinson's disease (PD). For many years there has been concern regarding its potential to be toxic to the dopaminergic cells of the substantia nigra. Much of the evidence to support this is derived from in vitro studies and there are significant limitations in extrapolating these data to the clinic. Indeed, there is no evidence to indicate that levodopa is toxic to PD patients, and even some suggestion that it may be protective.

摘要

左旋多巴是治疗帕金森病（PD）运动症状的“金标准”药物。多年来，人们一直担心它可能对黑质的多巴胺能细胞有毒性。支持这一观点的许多证据来自体外研究，而将这些数据外推至临床存在重大局限性。事实上，没有证据表明左旋多巴对PD患者有毒性，甚至有一些迹象表明它可能具有保护作用。